Compared with capecitabine-based regimens, fam-trastuzumab deruxtecan-nxki (T-DXd) led to higher response rates and longer survival in the third-line setting for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine (T-DM1), according to results from the phase III DESTINY-Breast02 trial presented by Ian Krop, MD, PhD, and colleagues at the 2022 San Antonio Breast Cancer Symposium (Abstract GS2-01).
T-DXd is an antibody-drug conjugate that uses the HER2-targeted antibody trastuzumab to deliver a cytotoxic payload selectively to HER2-expressing cells. In the single-arm DESTINY-Breast01 phase II clinical trial, T-DXd showed clinical activity in the third-line setting for patients with HER2-positive metastatic breast cancer who were previously treated with T-DM1, another HER2-targeted antibody-drug conjugate. These results led to the accelerated approval of T-DXd in 2019 as a third-line therapy for patients with metastatic or unresectable breast cancer who have received two or more prior HER2-targeted therapies.
“While DESTINY-Breast01 established T-DXd as a new treatment for this population, it was a modestly sized, single-arm phase II trial,” said Dr. Krop, Associate Cancer Center Director for Clinical Research and Chief Clinical Research Officer at the Yale Cancer Center. The DESTINY-Breast02 trial was designed as a confirmatory study for DESTINY-Breast01 to evaluate T-DXd vs treatment of physician’s choice in patients previously treated with T-DM1, he explained.
“In addition to confirming the favorable benefit-to-risk profile of T-DXd in this population, this research was also important to evaluate the efficacy of one antibody-drug conjugate, T-DXd, in patients whose cancer has already progressed on another antibody-drug conjugate, T-DM1,” Dr. Krop noted. “This is the first randomized trial to ask this important question.”
The results of DESTINY-Breast02 confirm the findings of DESTINY-Breast01, demonstrating high levels of efficacy of T-DXd in patients with HER2-positive metastatic breast cancer previously treated with T-DM1.... Furthermore, they extend these findings, demonstrating that T-DXd is not only highly active, but also superior to conventional chemotherapy-based regimens in this patient population.— Ian Krop, MD, PhD
Tweet this quote
DESTINY-Breast02
The DESTINY-Breast02 trial enrolled 608 patients whose metastatic breast cancers had progressed on or after T-DM1 treatment. Patients were randomly assigned 2:1 to receive either T-DXd or physician’s choice (a combination of capecitabine with either trastuzumab or lapatinib).
Among the patients treated with T-DXd, 69.7% experienced an objective response, as compared with 29.2% of patients treated with physician’s choice. Those treated with T-DXd were also 64% less likely to experience disease progression than patients receiving physician’s choice, with a median progression-free survival of 17.8 months and 6.9 months for patients in the T-DXd and physician’s choice arms, respectively. Overall survival was also significantly longer for patients treated with T-DXd (39.2 months with T-DXd vs 26.5 months with physician’s choice).
Dr. Krop noted that adverse events in patients who received T-DXd were consistent with prior studies. T-DXd–related interstitial lung disease was observed in 10.4% of patients who received the therapy; most cases were grade 1 or 2, but two cases of grade 5 interstitial lung disease were reported.
“The results of DESTINY-Breast02 confirm the findings of DESTINY-Breast01, demonstrating high levels of efficacy of T-DXd in patients with HER2-positive metastatic breast cancer previously treated with T-DM1,” said Dr. Krop. “Furthermore, they extend these findings, demonstrating that T-DXd is not only highly active, but also superior to conventional chemotherapy-based regimens in this patient population.”
Future Directions and Limitations
Follow-up analyses may assess patient-reported outcomes from this trial, and additional studies may examine adverse events, efficacy, and safety of the treatment in patients with metastases to the central nervous system, Dr. Krop noted. Ongoing studies are also evaluating T-DXd as a first-line therapy for patients with HER2-positive metastatic breast cancer and for patients with early-stage disease.
A limitation of this study was that the control arm was limited to therapies based on capecitabine, precluding direct comparison of T-DXd to treatment regimens containing other chemotherapeutic agents. An additional limitation is that patients with progressive metastases to the central nervous system were not eligible for the trial.
Disclosure: The DESTINY-Breast02 trial was designed and funded by Daiichi Sankyo in collaboration with AstraZeneca. Dr. Krop has received funding to his institution from AstraZeneca, Daiichi Sankyo, Genentech/Roche, MacroGenics, and Pfizer; consulting fees from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Genentech/Roche, MacroGenics, Seattle Genetics, and Taiho Oncology; and honoraria from AstraZeneca. Dr. Krop has participated on a data safety monitoring board or advisory board for Merck and Novartis, and his spouse holds a leadership position and stock in PureTech Health.
